Pain Medicine, Interventional Pain Medicine · Knoxville, TN
NPI
1457321648
Since 2006
Specialty
Pain Medicine, Interventional Pain Medicine
Code 208VP0014X
Group practices
5
Medicare group memberships
Hospitals
0
Hospital affiliations
1342 Papermill Pointe Way
Knoxville, TN, 37909
Phone (865) 673-5000
Groups this clinician bills Medicare through
Medicare paid, 2024
$201K
27,361 services
Medicare patients, 2024
259
Average age 65
Drug cost, 2024
$191K
565 prescriptions
Company payments, 2025
$4,201
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Adolfo J Cuadra was code J1010 (injection, methylprednisolone acetate, 1 mg), 7,451 times for 105 patients. In total Adolfo J Cuadra billed 27,361 services in 100 codes, and Medicare paid $201K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 7,451 | 105 | $0.10 | $734 |
| 99214 Office E&M - Established | Office | 81 | 61 | $82.84 | $6,710 |
| 20610 Joint Injection | Office | 76 | 50 | $47.95 | $3,644 |
| 82962 Clinical Chemistry | Office | 71 | 31 | $3.13 | $222 |
| 64636 Destruction by Neurolytic Agent - Back | Facility | 49 | 28 | $62.19 | $3,047 |
| 80307 Drug Tests | Office | 46 | 40 | $59.74 | $2,748 |
| G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 44 | 38 | $241.98 | $11K |
| 96138 Behavioral Health Services | Office | 35 | 29 | $21.70 | $760 |
| 62323 Nerve Block Injection - Back | Office | 35 | 23 | $170.90 | $5,981 |
| 64483 Nerve Block Injection - Back | Office | 35 | 16 | $222.58 | $7,790 |
| G0396 Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | Office | 35 | 29 | $22.50 | $787 |
| 96130 Behavioral Health Services | Office | 35 | 29 | $87.15 | $3,050 |
| 96132 Behavioral Health Services | Office | 35 | 29 | $90.65 | $3,173 |
| 64635 Destruction by Neurolytic Agent - Back | Facility | 33 | 29 | $204.03 | $6,733 |
| 64636 Destruction by Neurolytic Agent - Back | Office | 32 | 18 | $241.76 | $7,736 |
By year: 2022 $546K for 14,027 services; 2023 $195K for 21,233 services; 2024 $201K for 27,361 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 71 | 31 | $3.13 | $222 |
| 80307 Drug Tests | 46 | 40 | $59.74 | $2,748 |
| G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 44 | 38 | $241.98 | $11K |
Medicare prescription drug claims, 2024
In 2024, the drug Adolfo J Cuadra prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 105 prescriptions and refills. In total Adolfo J Cuadra wrote 565 Medicare prescriptions that cost $191K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 105 | 105 | 72 | $3,068 |
| Oxycodone Hcl Generic | 92 | 92 | 44 | $1,764 |
| Gabapentin Generic | 82 | 84 | 49 | $1,026 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 60 | 60 | 51 | $1,917 |
| Qutenza Capsaicin/Skin Cleanser | 48 | 138 | 28 | $174K |
| Cyclobenzaprine Hcl Generic | 23 | 23 | 13 | $284 |
| Meloxicam Generic | 19 | 19 | Under 11 | $24.49 |
| Baclofen Generic | 18 | 18 | Under 11 | $170 |
| Lidocaine Generic | 18 | 22 | 11 | $2,295 |
| Celecoxib Generic | 13 | 13 | Under 11 | $200 |
Brand drugs: 63 claims; generic drugs: 502 claims; opioid claims: 289.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Adolfo J Cuadra $4,201 ($4,201 in general payments such as food, travel and fees) from 13 companies. The largest payer was Spinefrontier, Inc. with $1,659.
| Company | Payments | Amount |
|---|---|---|
| Spinefrontier, Inc. | 9 | $1,659 |
| Boston Scientific Corporation BSX | 115 | $1,601 |
| Abbott Laboratories ABT | 25 | $456 |
| BIOTRONIK NRO, Inc. | 2 | $118 |
| Penumbra, Inc. PEN | 1 | $99.26 |
| Averitas Pharma Inc. | 2 | $93.8 |
| Si-Bone, Inc. SIBN | 2 | $41.11 |
| Abbvie Inc. ABBV | 1 | $30.17 |
| Saluda Medical Americas, Inc. | 1 | $28.31 |
| Hartmann USA, Inc. | 1 | $20.85 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.